Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Demeclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CASP7 | P55210 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demeclocycline SCHEMBL28251348 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL29487284 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL6549174 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL41287 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL23247280 | 0.99 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL29355123 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL20716691 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL20952687 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL3252 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL5503953 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1923 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| EP-4472649-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON ADMINISTRATION, AND USES | AGS Therapeutics SAS (FR) | 2024-12-11 | — | — | EP | claimed |
| WO-2024125656-A1 | USES OF DEMECLOCYCLINE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN TREATMENT OF TUMORS | 中南大学湘雅二医院 | 2024-06-20 | — | — | WO | claimed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| WO-2024104495-A1 | DEMECLOCYCLINE SALT EYE DROPS OR INJECTION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中南大学湘雅二医院 | 2024-05-23 | — | — | WO | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| CN-117482097-A | Application of Demeclocycline and pharmaceutically acceptable salts thereof in treatment of various tumors | 中南大学湘雅二医院 | 2024-02-02 | — | — | CN | claimed |
| US-6602516-B1 | Triiodomethane, Zinc oxide, barium sulfate, beeswax, and a tetracycline for root canal gutta percha points | MARTIN HOWARD (US) | 2003-08-05 | — | — | US | claimed |
| EP-0741570-B1 | PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO ANTIINFECTIVE MEDICATIONS | SEARLE & CO (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | claimed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| US-6172069-B1 | CONTROLLING TIME OF ADMINISTERING | G. D. SEARLE & COMPANY | 2001-01-09 | — | — | US | claimed |
| WO-1999056701-A1 | ANTIBIOTIC/MEDICATED GUTTA PERCHA POINT | MARTIN HOWARD (US) | 1999-11-11 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0201057-B1 | BONE TARGETED INHIBITORS OF CARBONIC ANHYDRASE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-12-02 | — | — | EP | claimed |
| US-5167964-A | Coating of blend of ethyl acrylate-methacrylic acid copolymer and povidone | WARNER-LAMBERT COMPANY (US) | 1992-12-01 | — | — | US | claimed |
| EP-0201057-A2 | Bone targeted inhibitors of carbonic anhydrase | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1986-11-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | MEN1 54/4885KMT2A 4042/4885TDP1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.